SCHEMBL6687693

SCHEMBL6687693

CCOc1cc(C2=NN(Cc3ccc(NC(=O)c4ccncc4)cc3)C(=O)OC2CC)ccc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PDE4D Q08499 6/20 0.43
PDE4A P27815 5/20 0.43
PDE4B Q07343 5/20 0.43
PDE4C Q08493 5/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.42
KMT2A Q03164 3/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6691419 0.97 SMN1; SMN2 (0.46) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6689118 0.95 LMNA (0.51) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6842687 0.94 LMNA (0.45) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL144775 0.92 SMN1; SMN2 (0.44) LMNAHTTSMN1; SMN2MAPK1PDE4D
SCHEMBL6841770 0.92 LMNA (0.46) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6689679 0.91 LMNA (0.43) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6683561 0.90 LMNA (0.44) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6683848 0.90 LMNA (0.44) LMNAHTTSMN1; SMN2MAPK1L3MBTL1
SCHEMBL6659691 0.90 NPC1 (0.46) LMNASMN1; SMN2PDE4DPDE4APDE4B
SCHEMBL6654883 0.90 PDE4D (0.41) LMNASMN1; SMN2MAPK1PDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B LMNA 2603/4885HTT 4819/4885SMN1; SMN2 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.